BRPI0406591A - Composição, métodos para o tratamento de uma doença neurodegenerativa, disquinesia, distonia, mioclonias ou tremores, psicose, de uma doença neuropsiquiátria, de uma condição doentia e enxaqueca, composto, métodos de inibição da atividade de um receptor de monoamina e da ativação de um receptor de monoamina métodos de identificação de polimorfismo genético e de um paciente apropriado para tratamento com o composto - Google Patents
Composição, métodos para o tratamento de uma doença neurodegenerativa, disquinesia, distonia, mioclonias ou tremores, psicose, de uma doença neuropsiquiátria, de uma condição doentia e enxaqueca, composto, métodos de inibição da atividade de um receptor de monoamina e da ativação de um receptor de monoamina métodos de identificação de polimorfismo genético e de um paciente apropriado para tratamento com o compostoInfo
- Publication number
- BRPI0406591A BRPI0406591A BR0406591-3A BRPI0406591A BRPI0406591A BR PI0406591 A BRPI0406591 A BR PI0406591A BR PI0406591 A BRPI0406591 A BR PI0406591A BR PI0406591 A BRPI0406591 A BR PI0406591A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compound
- treatment
- disease
- psychosis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 5
- 208000012661 Dyskinesia Diseases 0.000 title abstract 4
- 208000028017 Psychotic disease Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000004770 neurodegeneration Effects 0.000 title abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 3
- 206010071602 Genetic polymorphism Diseases 0.000 title abstract 2
- 208000014094 Dystonic disease Diseases 0.000 title 1
- 208000019695 Migraine disease Diseases 0.000 title 1
- 208000002033 Myoclonus Diseases 0.000 title 1
- 206010044565 Tremor Diseases 0.000 title 1
- 230000003213 activating effect Effects 0.000 title 1
- 208000010118 dystonia Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 206010027599 migraine Diseases 0.000 title 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 2
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 abstract 1
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 230000008484 agonism Effects 0.000 abstract 1
- 239000000002 anti-dyskinesia agent Substances 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000003137 locomotive effect Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000011809 primate model Methods 0.000 abstract 1
- 239000002469 receptor inverse agonist Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44140603P | 2003-01-16 | 2003-01-16 | |
US47934603P | 2003-06-17 | 2003-06-17 | |
PCT/US2004/001234 WO2004064738A2 (en) | 2003-01-16 | 2004-01-15 | Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0406591A true BRPI0406591A (pt) | 2005-12-20 |
BRPI0406591B1 BRPI0406591B1 (pt) | 2018-12-18 |
BRPI0406591B8 BRPI0406591B8 (pt) | 2021-05-25 |
Family
ID=32776052
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0406591A BRPI0406591B8 (pt) | 2003-01-16 | 2004-01-15 | composto e composição farmacêutica |
Country Status (22)
Country | Link |
---|---|
US (17) | US7601740B2 (pt) |
EP (2) | EP2009000B1 (pt) |
JP (2) | JP5184777B2 (pt) |
KR (1) | KR101095939B1 (pt) |
CN (3) | CN1816524B (pt) |
AT (2) | ATE512136T1 (pt) |
AU (1) | AU2004206886B2 (pt) |
BR (1) | BRPI0406591B8 (pt) |
CA (1) | CA2512639C (pt) |
CY (1) | CY1108642T1 (pt) |
DE (1) | DE602004016288D1 (pt) |
DK (2) | DK2009000T3 (pt) |
ES (2) | ES2367135T3 (pt) |
HK (2) | HK1083759A1 (pt) |
MX (1) | MXPA05007568A (pt) |
NZ (1) | NZ541146A (pt) |
PT (1) | PT1587789E (pt) |
RU (2) | RU2332401C2 (pt) |
SG (1) | SG170617A1 (pt) |
SI (2) | SI2009000T1 (pt) |
WO (1) | WO2004064738A2 (pt) |
ZA (1) | ZA200505680B (pt) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1263729B1 (en) * | 2000-03-06 | 2006-12-20 | Acadia Pharmaceuticals Inc. | Azacyclic compounds for use in the treatment of serotonin related diseases |
DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
US6911452B2 (en) * | 2001-12-28 | 2005-06-28 | Acadia Pharmaceuticals Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
MXPA04012893A (es) * | 2002-06-24 | 2005-03-31 | Acadia Pharm Inc | Derivados de piperidina n-substituidos como agentes receptores de serotonina. |
US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
KR101095939B1 (ko) | 2003-01-16 | 2011-12-19 | 아카디아 파마슈티칼스 인코포레이티드 | 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2a/2c 리셉터 역작용제 |
AU2004206931A1 (en) * | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US7855195B2 (en) * | 2003-12-02 | 2010-12-21 | Pharmaneuroboost N.V. | Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US7884096B2 (en) * | 2003-12-02 | 2011-02-08 | Pharmaneuroboost N.V. | Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US20050203130A1 (en) * | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
US20050119249A1 (en) * | 2003-12-02 | 2005-06-02 | Erik Buntinx | Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
CA2547639A1 (en) * | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
AU2005289635A1 (en) * | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and their preparation |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
KR20060030175A (ko) * | 2004-10-05 | 2006-04-10 | 경북대학교 산학협력단 | 무정위성 운동 치료용 약학조성물 |
AR060086A1 (es) * | 2006-03-24 | 2008-05-21 | Wyeth Corp | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos |
US20080051429A1 (en) * | 2006-04-19 | 2008-02-28 | Van Kammen Daniel | Use of 4-amino-piperidines for treating sleep disorders |
EP2037918A2 (en) * | 2006-05-15 | 2009-03-25 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
WO2008022154A2 (en) * | 2006-08-14 | 2008-02-21 | Wyeth | Methods of identifying agents for treating neurological disorders |
US20080254118A1 (en) * | 2007-04-11 | 2008-10-16 | Hans-Werner Wernersbach | Process for preparing pramipexole dihydrochloride tablets |
US20100151459A1 (en) * | 2007-01-26 | 2010-06-17 | Jun Soo Kwon | Marker for detecting the proposed efficacy of treatment |
CN101677971A (zh) | 2007-03-19 | 2010-03-24 | 阿卡蒂亚药品公司 | 5-ht2a反向激动剂和拮抗剂与抗精神病药物的组合 |
US20080254117A1 (en) * | 2007-04-10 | 2008-10-16 | Noel Cotton | Process for preparing pramipexole dihydrochloride tablets |
EP2150239A1 (en) * | 2007-04-24 | 2010-02-10 | Boehringer Ingelheim International GmbH | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
GB2463833B (en) * | 2007-06-26 | 2012-02-08 | Parkinson S Inst | Compositions that prevent or reverse alpha-synuclein fibrillation for use in the treatment of neurological disorders |
WO2009039461A2 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
DK2200610T3 (en) * | 2007-09-21 | 2018-04-23 | Acadia Pharm Inc | ADMINISTRATION OF PIMAVANSERIN WITH OTHER AGENTS |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
RS57110B1 (sr) | 2008-10-28 | 2018-06-29 | Arena Pharm Inc | Sastavi modulatora 5-ht2a serotoninskog receptora korisni za tretiranje poremećaja povezanih sa njim |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
ES2727815T3 (es) | 2012-04-14 | 2019-10-18 | Intra Cellular Therapies Inc | Tratamiento del TEPT y de trastornos del control de impulsos |
US9446037B2 (en) | 2012-11-27 | 2016-09-20 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
KR102495941B1 (ko) | 2013-12-03 | 2023-02-06 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
TWI690512B (zh) * | 2014-03-07 | 2020-04-11 | 瑞士商赫爾辛保健股份有限公司 | 對位取代的不對稱脲及其醫療用途 |
CN104961671B (zh) * | 2014-09-05 | 2018-01-02 | 苏州晶云药物科技有限公司 | N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法 |
CN114146088A (zh) * | 2015-01-28 | 2022-03-08 | 杜克大学 | 用于治疗神经精神类障碍的组合物及方法 |
US10343993B2 (en) | 2015-03-02 | 2019-07-09 | Pliva Hrvatska D.O.O. | Processes and intermediates for the preparation of Pimavanserin |
AU2016291673A1 (en) | 2015-07-15 | 2018-01-25 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
SI3325444T1 (sl) | 2015-07-20 | 2021-11-30 | Acadia Pharmaceuticals Inc. | Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C |
CZ2015601A3 (cs) | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
CZ2015688A3 (cs) | 2015-10-02 | 2017-04-12 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů |
CN105523993A (zh) * | 2015-12-28 | 2016-04-27 | 重庆两江药物研发中心有限公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用 |
ES2940659T3 (es) | 2016-03-22 | 2023-05-10 | Helsinn Healthcare Sa | Ureas asimétricas de bencenosulfonilo y usos médicos de las mismas |
WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017172757A1 (en) | 2016-03-29 | 2017-10-05 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
CN107343887A (zh) * | 2016-05-06 | 2017-11-14 | 常州爱诺新睿医药技术有限公司 | 一种无定型半酒石酸匹莫范色林与药用辅料的固体分散体及其制备方法 |
CN106179449B (zh) * | 2016-07-18 | 2018-11-13 | 南京工业大学 | 一种碳氮材料负载的钴催化剂及合成哌马色林中间体的方法 |
AU2017326253B2 (en) | 2016-09-13 | 2021-10-21 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
US11331316B2 (en) | 2016-10-12 | 2022-05-17 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
WO2018118626A1 (en) | 2016-12-20 | 2018-06-28 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
CA3054841A1 (en) | 2017-03-24 | 2018-09-27 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
US11135211B2 (en) | 2017-04-28 | 2021-10-05 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
BR112019024817A2 (pt) | 2017-05-25 | 2020-08-18 | Glytech Llc. | formulações para tratamento de distúrbio de estresse pós-traumático |
CN110996948A (zh) | 2017-06-12 | 2020-04-10 | 格莱泰施有限责任公司 | 用nmda拮抗剂和d2/5ht2a或选择性5ht2a拮抗剂治疗抑郁症 |
CN109111385B (zh) * | 2017-06-23 | 2023-06-30 | 上海翰森生物医药科技有限公司 | 5-ht2a受体抑制剂及其制备方法和应用 |
CN111132976B (zh) | 2017-08-21 | 2023-08-22 | 阿卡蒂亚药品公司 | 化合物、其盐和用于治疗疾病的方法 |
EP3672960A2 (en) | 2017-08-21 | 2020-07-01 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and their use for the treatment of diseases |
EP3675827A1 (en) | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
CN109568278A (zh) * | 2017-09-28 | 2019-04-05 | 北京万全德众医药生物技术有限公司 | 匹莫范色林片剂及其制备方法 |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
EP3709999B1 (en) * | 2017-11-13 | 2024-02-14 | Texas Tech University System | Compositions and methods for treating cancer |
KR102036909B1 (ko) * | 2017-11-28 | 2019-10-25 | 한국과학기술원 | 신규 디스토니아 치료용 약학적 조성물 |
MX2020009668A (es) | 2018-03-16 | 2021-01-08 | Intra Cellular Therapies Inc | Métodos novedosos. |
IT201800003736A1 (it) | 2018-03-19 | 2019-09-19 | Lundbeck Pharmaceuticals Italy S P A | Processo per la produzione di Pimavanserin |
US20190359985A1 (en) * | 2018-05-22 | 2019-11-28 | John Lawrence Mee | Adjustable method for sustainable human cognitive enhancement |
CN108947891B (zh) | 2018-07-26 | 2021-02-09 | 丽珠集团新北江制药股份有限公司 | 利用三光气安全制备匹莫范色林及其酒石酸盐的方法 |
WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
IT201800009690A1 (it) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | Processo per la produzione di pimavanserina |
CA3130767A1 (en) | 2019-02-27 | 2020-09-03 | The Regents Of The University Of California | N-substituted indoles and other heterocycles for treating brain disorders |
BR112021016620A2 (pt) | 2019-02-27 | 2021-11-03 | Univ California | Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais |
AU2020259406A1 (en) | 2019-04-17 | 2021-11-04 | Compass Pathfinder Limited | Treatment of depression and other various disorders with psilocybin |
US20220288048A1 (en) | 2019-07-22 | 2022-09-15 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder |
KR102227268B1 (ko) * | 2019-10-07 | 2021-03-12 | 한국과학기술원 | 디스토니아 치료 후보 약물의 신규 스크리닝 방법 |
CN113214141B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其制备和应用 |
WO2021147818A1 (zh) * | 2020-01-21 | 2021-07-29 | 瀚远医药有限公司 | 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用 |
CN115677723B (zh) * | 2020-01-21 | 2024-06-04 | 瀚远医药有限公司 | 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用 |
WO2021206741A1 (en) * | 2020-04-09 | 2021-10-14 | Delahoussaye Kevin | Modulating neurotransmitter concentration |
JP2023535926A (ja) * | 2020-07-22 | 2023-08-22 | 嘉奥制薬(石家庄)有限公司 | 5-ht2a受容体阻害剤又は逆作動薬、その調製方法、及びその用途 |
US11071739B1 (en) | 2020-09-29 | 2021-07-27 | Genus Lifesciences Inc. | Oral liquid compositions including chlorpromazine |
JP2023549174A (ja) * | 2020-11-04 | 2023-11-22 | グリアセルテック・インコーポレイテッド | クロルプロマジンを含む神経炎症性疾患の予防または治療用組成物 |
CN113292484B (zh) * | 2021-06-04 | 2022-11-15 | 沈阳药科大学 | 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用 |
Family Cites Families (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA684843A (en) | 1964-04-21 | P. Roberts Cecil | Cap aligning mechanism | |
US165225A (en) * | 1875-07-06 | Improvement in hubs | ||
BE794333A (fr) | 1972-01-20 | 1973-07-19 | Wyeth John & Brother Ltd | Composes heterocycliques azotes therapeutiques |
GB1507462A (en) * | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
US3983234A (en) * | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
JPS5152176A (pt) | 1974-10-12 | 1976-05-08 | Yoshitomi Pharmaceutical | |
JPS528517A (en) | 1975-07-09 | 1977-01-22 | Toyo Autom Kk | Fluid line automatic closing system at an earthquake |
GB1586468A (en) * | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
CA1140119A (en) | 1978-04-03 | 1983-01-25 | Joseph Torremans | N-heterocyclyl-4-piperidinamines |
US4255432A (en) * | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
US4332804A (en) * | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
GB8527052D0 (en) * | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
GB8621892D0 (en) | 1986-09-11 | 1986-10-15 | Lundbeck & Co As H | Organic compound |
FR2642069B1 (fr) | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5214055A (en) * | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
US5216165A (en) * | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
IT1252227B (it) | 1991-12-17 | 1995-06-05 | Ciba Geigy Spa | Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici |
JPH05208517A (ja) | 1992-01-31 | 1993-08-20 | Nec Corp | 印字制御回路 |
US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
CA2123728A1 (en) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
WO1994027967A1 (en) | 1993-05-26 | 1994-12-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
TW394760B (en) * | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
DE4404183A1 (de) * | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
CA2233204A1 (en) | 1995-09-29 | 1997-04-03 | Joseph A. Jakubowski | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
WO1997020553A1 (en) * | 1995-12-07 | 1997-06-12 | Javitt Daniel C | Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists |
WO1997038665A2 (en) | 1996-04-03 | 1997-10-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
ES2218677T3 (es) | 1996-04-17 | 2004-11-16 | Bristol-Myers Squibb Pharma Company | Derivados de n-(amidinofenil)-n'-(subst.)-3h-2,4-benzodiazepin-3-ona como inhibidores del factor xa. |
US5869488A (en) * | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5965571A (en) * | 1996-08-22 | 1999-10-12 | New York University | Cholinesterase inhibitors for treatment of Parkinson's disease |
US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
NZ334543A (en) | 1996-09-10 | 2000-06-23 | Thomae Gmbh Dr K | Modified amino acids for production of antibodies and labelled compounds suitable for RIA and ELISA assays |
DE19643331A1 (de) | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
JP2001525809A (ja) | 1997-05-08 | 2001-12-11 | スミスクライン・ビーチャム・コーポレイション | プロテアーゼ阻害剤 |
GB9718833D0 (en) * | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
ES2156845T1 (es) | 1998-04-14 | 2001-08-01 | Arena Pharm Inc | Receptores de serotonina humana no endogenos constitutivamente activados y moduladores de moleculas pequeñas para estos. |
US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
GB9816263D0 (en) * | 1998-07-24 | 1998-09-23 | Merck Sharp & Dohme | Therapeutic agents |
US6358698B1 (en) | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
CN1198613C (zh) | 1998-10-16 | 2005-04-27 | 第一三得利制药株式会社 | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 |
US6150393A (en) * | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
US6725038B1 (en) | 1999-01-26 | 2004-04-20 | Nokia Corporation | Method and apparatus for speeding up AAL2 connection setup during handover in advanced cellular networks |
CA2367112A1 (en) | 1999-03-24 | 2000-09-28 | The Regents Of The University Of California | Methods for treating neurodegenerative disorders using aspartyl protease inhibitors |
US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
CA2373892A1 (en) | 1999-05-17 | 2000-11-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
US20050148018A1 (en) * | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
US7022698B2 (en) * | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
US6834122B2 (en) | 2000-01-22 | 2004-12-21 | Kairos Scientific, Inc. | Visualization and processing of multidimensional data using prefiltering and sorting criteria |
EP1263729B1 (en) * | 2000-03-06 | 2006-12-20 | Acadia Pharmaceuticals Inc. | Azacyclic compounds for use in the treatment of serotonin related diseases |
GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
DE60141752D1 (de) * | 2000-06-30 | 2010-05-20 | Innogenetics Nv | Differentielle diagnose von neurologischen krankheiten |
HUP0303360A2 (hu) | 2000-09-25 | 2004-01-28 | Actelion Pharmaceuticals Ltd. | Maláriaellenes hatású szubsztituált amino-aza-cikloalkánok és ezeket tartalmazó gyógyszerkészítmények |
US20020156068A1 (en) * | 2001-03-22 | 2002-10-24 | Behan Dominic P. | Anti-psychosis combination |
GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
US6911452B2 (en) * | 2001-12-28 | 2005-06-28 | Acadia Pharmaceuticals Inc. | Spiroazacyclic compounds as monoamine receptor modulators |
WO2003062206A2 (en) | 2002-01-23 | 2003-07-31 | Arena Pharmaceuticals, Inc. | Small molecule modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
MXPA04012893A (es) * | 2002-06-24 | 2005-03-31 | Acadia Pharm Inc | Derivados de piperidina n-substituidos como agentes receptores de serotonina. |
US7538222B2 (en) * | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
US7253186B2 (en) * | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
AU2003284899A1 (en) | 2002-10-29 | 2004-05-25 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
KR101095939B1 (ko) * | 2003-01-16 | 2011-12-19 | 아카디아 파마슈티칼스 인코포레이티드 | 신경퇴행성 질환에 대한 치료제로서 선택적 세로토닌2a/2c 리셉터 역작용제 |
AU2004206931A1 (en) | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
CA2547639A1 (en) | 2003-12-02 | 2005-06-16 | B&B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
DE602004020263D1 (de) | 2003-12-22 | 2009-05-07 | Acadia Pharm Inc | Amino-substituierte diaryläa,dücyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen |
US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
US7820695B2 (en) | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
AU2005289635A1 (en) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide and their preparation |
US7790899B2 (en) | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
JP4999704B2 (ja) | 2005-01-10 | 2012-08-15 | タヘリ ラドュカ エルエルシー | 体内に埋設可能なデバイスを配備する装置および方法 |
JP2008534593A (ja) | 2005-03-30 | 2008-08-28 | メルク エンド カムパニー インコーポレーテッド | グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法 |
US8572080B2 (en) | 2010-06-04 | 2013-10-29 | Salesforce.Com, Inc. | Methods and systems for analyzing a network feed in a multi-tenant database system environment |
US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
US9446037B2 (en) * | 2012-11-27 | 2016-09-20 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
US10953000B2 (en) * | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
WO2017165635A1 (en) * | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
EP3675827A1 (en) * | 2017-08-30 | 2020-07-08 | Acadia Pharmaceuticals Inc. | Formulations of pimavanserin |
-
2004
- 2004-01-15 KR KR1020057013195A patent/KR101095939B1/ko active IP Right Grant
- 2004-01-15 CN CN2004800044790A patent/CN1816524B/zh not_active Expired - Lifetime
- 2004-01-15 AU AU2004206886A patent/AU2004206886B2/en not_active Expired
- 2004-01-15 PT PT04702584T patent/PT1587789E/pt unknown
- 2004-01-15 EP EP08015449A patent/EP2009000B1/en not_active Expired - Lifetime
- 2004-01-15 DE DE602004016288T patent/DE602004016288D1/de not_active Expired - Lifetime
- 2004-01-15 ES ES08015449T patent/ES2367135T3/es not_active Expired - Lifetime
- 2004-01-15 SI SI200431728T patent/SI2009000T1/sl unknown
- 2004-01-15 SI SI200430956T patent/SI1587789T1/sl unknown
- 2004-01-15 ES ES04702584T patent/ES2314362T3/es not_active Expired - Lifetime
- 2004-01-15 DK DK08015449.5T patent/DK2009000T3/da active
- 2004-01-15 US US10/759,561 patent/US7601740B2/en active Active
- 2004-01-15 DK DK04702584T patent/DK1587789T3/da active
- 2004-01-15 EP EP04702584A patent/EP1587789B1/en not_active Expired - Lifetime
- 2004-01-15 MX MXPA05007568A patent/MXPA05007568A/es active IP Right Grant
- 2004-01-15 CN CN2010105460287A patent/CN102028949A/zh active Pending
- 2004-01-15 AT AT08015449T patent/ATE512136T1/de not_active IP Right Cessation
- 2004-01-15 WO PCT/US2004/001234 patent/WO2004064738A2/en active Application Filing
- 2004-01-15 NZ NZ541146A patent/NZ541146A/en not_active IP Right Cessation
- 2004-01-15 CN CN200910225582.2A patent/CN101780080B/zh not_active Expired - Lifetime
- 2004-01-15 SG SG200705308-5A patent/SG170617A1/en unknown
- 2004-01-15 RU RU2005125918/04A patent/RU2332401C2/ru active
- 2004-01-15 BR BRPI0406591A patent/BRPI0406591B8/pt active IP Right Grant
- 2004-01-15 AT AT04702584T patent/ATE407117T1/de active
- 2004-01-15 JP JP2006501009A patent/JP5184777B2/ja not_active Expired - Lifetime
- 2004-01-15 CA CA2512639A patent/CA2512639C/en not_active Expired - Lifetime
-
2005
- 2005-07-14 ZA ZA200505680A patent/ZA200505680B/en unknown
-
2006
- 2006-03-30 HK HK06103961.3A patent/HK1083759A1/xx not_active IP Right Cessation
- 2006-03-30 HK HK09105896.5A patent/HK1126776A1/xx not_active IP Right Cessation
- 2006-05-03 US US11/416,855 patent/US7659285B2/en active Active
- 2006-05-03 US US11/416,527 patent/US7732462B2/en active Active
- 2006-05-03 US US11/416,594 patent/US7713995B2/en active Active
-
2008
- 2008-04-16 RU RU2008115009/04A patent/RU2465267C2/ru active
- 2008-12-03 CY CY20081101402T patent/CY1108642T1/el unknown
-
2010
- 2010-03-10 JP JP2010053450A patent/JP2010174026A/ja active Pending
- 2010-04-13 US US12/759,664 patent/US8008323B2/en not_active Expired - Lifetime
- 2010-04-13 US US12/759,662 patent/US7994193B2/en not_active Expired - Lifetime
-
2011
- 2011-06-27 US US13/169,893 patent/US8227487B2/en not_active Expired - Lifetime
-
2012
- 2012-06-29 US US13/539,011 patent/US8377959B2/en not_active Expired - Lifetime
-
2013
- 2013-01-25 US US13/750,778 patent/US8618130B2/en not_active Expired - Lifetime
- 2013-11-21 US US14/086,838 patent/US8921393B2/en not_active Expired - Lifetime
-
2014
- 2014-11-10 US US14/537,793 patent/US9211289B2/en not_active Expired - Lifetime
-
2015
- 2015-11-06 US US14/935,246 patent/US9566271B2/en not_active Expired - Lifetime
-
2017
- 2017-01-03 US US15/397,582 patent/US10028944B2/en not_active Expired - Lifetime
-
2018
- 2018-06-26 US US16/019,485 patent/US10525046B2/en not_active Expired - Lifetime
-
2019
- 2019-11-18 US US16/687,467 patent/US20200323836A1/en not_active Abandoned
-
2021
- 2021-01-29 US US17/162,476 patent/US20240091212A1/en active Pending
- 2021-09-14 US US17/474,816 patent/US20220241265A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0406591A (pt) | Composição, métodos para o tratamento de uma doença neurodegenerativa, disquinesia, distonia, mioclonias ou tremores, psicose, de uma doença neuropsiquiátria, de uma condição doentia e enxaqueca, composto, métodos de inibição da atividade de um receptor de monoamina e da ativação de um receptor de monoamina métodos de identificação de polimorfismo genético e de um paciente apropriado para tratamento com o composto | |
BRPI0911482A2 (pt) | Uso de epotilona d no tratamento de doenças associadas a tau incluindo doenças de alzheimer | |
BRPI0409128A (pt) | uso de antagonistas de opióides periféricos, especialmente metilnaltrexona para tratar sìndrome de intestino irritável | |
BR0013010B1 (pt) | Formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina | |
BRPI0409634A (pt) | ligantes de receptores de canabinóides e utilização destes | |
BR112013009203A2 (pt) | montagens de encaixe oral | |
BRPI1009842B8 (pt) | uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas | |
ATE555814T1 (de) | Radioaktive mittel für die in vivo pet-bildgebung von ccr5 | |
ATE551959T1 (de) | Vorrichtung zur fixierung und/oder manipulation von gewebe | |
BRPI0510947A (pt) | tratamento de doença respiratória | |
WO2009032057A3 (en) | Method for the selective therapy of disease | |
BRPI0608032A2 (pt) | composição para o cuidado do cabelo e/ou do couro cabeludo, método para tratar e/ou prevenir as afecções inflamatórias da pele, uso de um composto de amino-oxo-indol-ilideno e uso de uma composição | |
LLLLGGGLGGG | Medicines and healthcare products regulatory agency | |
TW200735842A (en) | Portable tele-homecare monitor system and method for the same | |
BRPI0413366A (pt) | método para aperfeiçoamento genético de porcos terminais | |
BRPI0415781A (pt) | método para o tratamento de diabetes em um paciente e kit farmacêutico | |
Douglas et al. | Health implications of sanitation in a public abattoir in Port Harcourt, Nigeria | |
BRPI0517950A (pt) | uso de andrógenos para reduzir a probabilidade de adquirir ou para o tratamento do envelhecimento da pele | |
Kwok et al. | Targeting inhibitory chondroitin sulphate proteoglycans to promote plasticity after injury | |
BR112012008193A2 (pt) | composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor | |
MX2010005915A (es) | Derivados de fenil-oxetanilo. | |
EP1885851A4 (en) | METHODS OF DIAGNOSING THE TRANGENERAL EFFECTS OF ENVIRONMENTAL TOXIC SUBSTANCES ON MAMMALIAN GERMINAL CELLS AND TREATING ASSOCIATED DISEASES | |
EP1961295A3 (en) | Elastic bandage for horses' legs and relative method of realisation | |
DE60203256D1 (de) | System für eine implantierbare medizinische Vorrichtung | |
HN2010001176A (es) | Aminotiazoles y sus usos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15V | Prolongation of time limit allowed |
Free format text: RECONHECIDO OBSTACULO ADMINSTRATIVO E DEVOLVIDO O PRAZO DE 54 DIAS, NOS TERMOS DO ARTIGO 221 2O DA LPI E RESOLUCAO 116/2004 . |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: ESCLARECER, EM ATE 60 (SESSENTA) DIAS, APRESENTANDO DOCUMENTACAO COMPROBATORIA, A INCLUSAO DOS INVENTORES NORMAN NASH, CARL-MAGNUS A. ANDERSON E ALLAN K. ULDAM CONSTANTE NA NO 018090000134 DE 05/01/2009 E NAO INCLUSA NA PUBLICACAO INTERNACIONAL WO/2004/064738 DE 05/05/2004, UMA VEZ QUE A DOCUMENTACAO APRESENTADA NA MESMA FAZ MENCAO SOMENTE AO PEDIDO DE PATENTE US 10/759,561 DE 15/01/2004 E NAO AO PEDIDO PCT/US2004/001234 E NAO HA DOCUMENTACAO DISPONIVEL QUE CORRELACIONE ESTES PEDIDOS. |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/12/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B25G | Requested change of headquarter approved |
Owner name: ACADIA PHARMACEUTICALS, INC (US) |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B25G | Requested change of headquarter approved |
Owner name: ACADIA PHARMACEUTICALS, INC (US) |